- Home
- AGAE vs MRKR Comparison
AGAE vs MRKR Comparison
Compare AGAE & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- MRKR
- Stock Information
- Founded
- AGAE 2017
- MRKR N/A
- Country
- AGAE United States
- MRKR United States
- Employees
- AGAE N/A
- MRKR N/A
- Industry
- AGAE Cable & Other Pay Television Services
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- AGAE Telecommunications
- MRKR Health Care
- Exchange
- AGAE Nasdaq
- MRKR Nasdaq
- Market Cap
- AGAE 35.0M
- MRKR 30.7M
- IPO Year
- AGAE N/A
- MRKR N/A
- Fundamental
- Price
- AGAE $0.90
- MRKR $2.46
- Analyst Decision
- AGAE
- MRKR Strong Buy
- Analyst Count
- AGAE 0
- MRKR 1
- Target Price
- AGAE N/A
- MRKR $19.00
- AVG Volume (30 Days)
- AGAE 31.1K
- MRKR 55.9K
- Earning Date
- AGAE 11-14-2024
- MRKR 11-14-2024
- Dividend Yield
- AGAE N/A
- MRKR N/A
- EPS Growth
- AGAE N/A
- MRKR N/A
- EPS
- AGAE N/A
- MRKR N/A
- Revenue
- AGAE $9,256,023.00
- MRKR $5,395,849.00
- Revenue This Year
- AGAE N/A
- MRKR $64.48
- Revenue Next Year
- AGAE N/A
- MRKR N/A
- P/E Ratio
- AGAE N/A
- MRKR N/A
- Revenue Growth
- AGAE 36.15
- MRKR 79.04
- 52 Week Low
- AGAE $0.61
- MRKR $2.44
- 52 Week High
- AGAE $1.57
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- AGAE 52.71
- MRKR 35.15
- Support Level
- AGAE $0.89
- MRKR $2.50
- Resistance Level
- AGAE $0.93
- MRKR $2.79
- Average True Range (ATR)
- AGAE 0.07
- MRKR 0.23
- MACD
- AGAE 0.02
- MRKR -0.07
- Stochastic Oscillator
- AGAE 47.23
- MRKR 0.00
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.